---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-257347"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:25:03.031921+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvalent Q3 net loss $122.4M; completes NDA for zidesamtinib; cash $943M into 2028

## Summary
- Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC.
- On track to report topline pivotal data for neladalkib in ALK-positive NSCLC by year-end 2025.
- Cash, cash equivalents and marketable securities of $943.1M as of Sept 30, 2025; expected runway into 2028.
- Q3 2025 net loss of $122.4M, R&D expenses $83.8M, G&A expenses $28.9M.
- Presented preliminary data for neladalkib in ALK-positive solid tumors at ESMO and preclinical data for NVL-330 in HER2-altered NSCLC.

## SEC filing metadata
- accession: 0001193125-25-257347
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000119312525257347/0001193125-25-257347-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000119312525257347/nuvl-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-257347
- JSON: https://secwatch.observer/filing/0001193125-25-257347.json
- Plain text: https://secwatch.observer/filing/0001193125-25-257347.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.